Experimental immune therapy takes aim at Hard-to-Treat cancers
NCT ID NCT06556108
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells that carry a protein called ALPP. The main goals were to check safety and see if the treatment could shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALPP CAR-T cells (genetically engineered immune cells targeting a protein on tumor cells), along with chemotherapy drugs fludarabine and cyclophosphamide
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This was a very small pilot study with only 5 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects, and it is unclear if targeting ALPP will be effective or safe in larger groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Hematology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China